Sirona (Nasdaq: SIRO), the dental technology leader, today announced its
financial results for the quarter and fiscal year ended September 30,
2012.
Fourth Quarter Fiscal 2012 vs. Fourth Quarter Fiscal 2011 Financial
Results
Revenue was $247.4 million, an increase of $28.6 million or up 13.1%
(and up 23.4% on a constant currency basis). The Company's business
segments grew as follows: CAD/CAM Systems increased 25.6% (up 36.5% on a
constant currency basis), Treatment Centers increased 13.2% (up 28.0% on
a constant currency basis), Imaging Systems increased 6.9% (up 14.0% on
a constant currency basis), and Instruments increased 1.0% (up 14.0% on
a constant currency basis).
Revenue in the United States increased 34.1%, while revenues outside the
United States increased 5.7% (up 19.2% constant currency), with
particularly robust performance in the Asia-Pacific region.
Gross profit was $132.1 million, up $21.4 million. Gross profit margin
was 53.4% in the fourth quarter of Fiscal 2012, compared to 50.6% in the
prior year. Gross profit margin as a percent of sales was positively
impacted by better segment gross profit margin and lower amortization.
Fourth quarter 2012 operating income excluding amortization expense was
$57.1 million (operating income of $45.4 million plus amortization
expense of $11.7 million), compared to $45.5 million (operating income
of $25.0 million plus amortization expense of $13.9 million, plus a $6.6
million non-cash compensation charge) in the fourth quarter of 2011.
Net income for the fourth quarter of 2012 was $34.7 million, or $0.62
per diluted share, versus $13.8 million, or $0.24 per diluted share in
the prior year period. Non-GAAP earnings per diluted share for the
fourth quarter of 2012 was $0.71 compared to $0.68 in the prior year
quarter.
At September 30, 2012, the Company had cash and cash equivalents of
$151.1 million and total debt of $75.5 million, resulting in net cash of
$75.6 million. This compares to net debt of $22.5 million at September
30, 2011.
Jost Fischer, Chairman and CEO of Sirona commented: “We had an
outstanding fourth quarter, with every segment of our business growing
double digits, constant currency and strong operating income growth.
Fiscal 2012 was another year of double digit constant currency revenue
growth for Sirona, where we exceeded sales expectations. We posted
record revenues and earnings, strengthened our balance sheet, extended
our global leadership position and introduced the revolutionary Omnicam.
Our 12.6% constant currency revenue growth was particularly noteworthy
compared to a record setting fiscal 2011 in which Sirona grew over 16%
constant currency.”
Mr. Fischer continued: “For the year, Treatment Centers and CAD/CAM led
our growth, up 15.1% and 13.9% respectively on a constant currency
basis. Revenue growth was particularly strong in non-European
international markets, led again by the Asia-Pacific region. The U.S.
continues to improve for us, accelerating for the third consecutive
quarter, ending up a robust 11.4% for the year. Although Germany was
down due to a difficult IDS comparison to last year, we had our second
best year ever in Germany, and the rest of Europe grew this quarter and
for the year, on a constant currency basis. We ended our year with an
unprecedented celebration at CEREC 27.5 where we received a standing
ovation from a crowd of around 4,000 dental professionals with the
launch of the revolutionary Omnicam. With the investment in our global
sales and service infrastructure continuing to pay dividends and
innovation as our top priority, we expect our momentum to continue into
next year as reflected in our revenue guidance.”
Fiscal 2013 Guidance
Management anticipates fiscal year 2013 constant currency revenue growth
to be in the range of 9% to 11%, and EPS on a non-GAAP adjusted basis^
in a range of $3.33 to $3.43 (reflecting growth of approximately 10% to
13%).
Fiscal 2012 vs. Fiscal 2011 Financial Results
Revenue was $979.4 million, an increase of $65.5 million or up 7.2% (up
12.6% on a constant currency basis). The Company's business segments
grew as follows: CAD/CAM Systems increased 9.1% (up 13.9% on a constant
currency basis), Imaging Systems increased 7.4% (up 11.5% on a constant
currency basis), Treatment Centers increased 7.2% (up 15.1% on a
constant currency basis), and Instruments increased 0.2% (up 7.5% on a
constant currency basis).
Revenue in the United States increased 11.4%, while revenues outside the
United States increased 5.5% (up 13.2% constant currency), with
particularly robust performance in the Asia-Pacific region.
Gross profit was $524.0 million, up $40.3 million. Gross profit margin
was 53.5% for Fiscal 2012, compared to 52.9% in the prior year. Gross
profit margin as a percent of sales was positively impacted by lower
amortization.
Fiscal 2012 operating income excluding amortization expense was $233.7
million (operating income of $185.7 million plus amortization expense of
$47.9 million). This compares to 2011 operating income excluding
amortization and a non-cash compensation charge of $222.5 million
(operating income of $160.9 million plus amortization expense of $54.9
million, plus the $6.6 million charge).
Conference Call/Webcast Information
Sirona will hold a conference call to discuss its financial results at
8:30 a.m. Eastern Time on November 16, 2012. The teleconference can be
accessed by calling +1 800.299.7635 (domestic) or +1 617.786.2901
(international) using passcode # 43749778. The webcast will be available
via the Internet at http://ir.sirona.com
and a presentation relating to the call will be available on our
website. A replay of the conference call will be available through
November 23, 2012 by calling +1 888 286 8010 (domestic) or +1 617 801
6888 (international) using passcode #17050016. A web archive will be
available for 30 days at www.sirona.com.
About Sirona Dental Systems, Inc.
Sirona, the dental technology leader, has served dealers and dentists
worldwide for more than 130 years. Sirona develops, manufactures, and
markets a complete line of dental products, including CAD/CAM
restoration systems (CEREC), digital intra-oral, panoramic and 3D
imaging systems, dental treatment centers and handpieces. Visit http://www.sirona.com
for more information about Sirona and its products.
This press release contains forward-looking information about Sirona
Dental Systems, Inc.’s financial results, guidance and estimates,
business prospects, and products and services that involve substantial
risks and uncertainties or other factors that may cause actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. You can identify these statements by the use
of words such as "may," "could," "estimate," "will," "believe,"
"anticipate," "think," "intend," "expect," "project," "plan," "target,"
"forecast", and similar words and expressions which identify
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of
future performance and involve known and unknown risks and
uncertainties, and other factors. Readers are cautioned not to place
undue reliance on such statements, which speak only as of the date
hereof. For a discussion of such risks, uncertainties and other matters
that could cause actual results to differ materially, including risks
relating to, among other factors, the market for dental product and
services, pricing, future sales volume of the Company's products, the
possibility of changing economic, market and competitive conditions,
dependence on products, dependence on key personnel, technological
developments, intense competition, market uncertainties, dependence on
distributors, ability to manage growth, dependence on key suppliers,
dependence on key members of management, government regulation,
acquisitions and affiliations and currency exchange rate fluctuations,
readers are urged to carefully review and consider various disclosures
made by the Company in its Annual Report on Form 10-K and in its reports
on Forms 10-Q and 8-K filed with the U.S. Securities and Exchange
Commission, which can be accessed through the SEC’s website, www.sec.gov.
This presentation contains non GAAP financial measures, which should not
be viewed in isolation and do not purport to be an alternative to net
income (loss) as an indicator of operating performance or an alternative
to cash flows from operating activities as a measure of liquidity. The
Company assumes no obligation to and expressly disclaims any obligation
to update or revise any forward-looking statements contained in this
document to reflect new information or future events or developments
after the date any such statement is made.
_______________
* Operating income plus amortization and constant currency growth
and results are non-GAAP financial measures that exclude certain items.
Please refer to "Reconciliation of GAAP and non-GAAP Information
(unaudited)” in the attached exhibits for a description of these items.
^This metric is a new, non-GAAP financial measure that excludes
certain items. Please refer to "Reconciliation of GAAP and non-GAAP
Information (unaudited)” in the attached exhibits for a description of
these items. The 10% to 13% growth rate for non-GAAP Adjusted EPS
compares this new metric for fiscal 2013 guidance to fiscal 2012
non-GAAP Adjusted EPS re-calculated on the same basis.
|
|
|
|
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED
CONSOLIDATED STATEMENT OF INCOME
|
|
|
|
|
|
|
UNAUDITED
Three months ended
September 30,
|
|
|
|
Year ended
September 30,
|
|
|
|
|
2012
|
|
|
2011
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
$'000s (except per share amounts)
|
|
|
|
$'000s (except per share amounts)
|
|
Revenue
|
|
$
|
247,364
|
|
$
|
218,797
|
|
|
$
|
979,351
|
|
$
|
913,866
|
|
Cost of sales
|
|
|
115,285
|
|
|
108,080
|
|
|
|
455,400
|
|
|
430,214
|
|
Gross profit
|
|
|
132,079
|
|
|
110,717
|
|
|
|
523,951
|
|
|
483,652
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expense
|
|
|
76,912
|
|
|
74,637
|
|
|
|
295,659
|
|
|
277,081
|
|
Research and development
|
|
|
12,606
|
|
|
13,485
|
|
|
|
52,622
|
|
|
55,530
|
|
Provision for doubtful accounts and notes receivable
|
|
|
(338)
|
|
|
62
|
|
|
|
(75)
|
|
|
96
|
|
Net other operating income
|
|
|
(2,500)
|
|
|
(2,500)
|
|
|
|
(10,000)
|
|
|
(10,000)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
45,399
|
|
|
25,033
|
|
|
|
185,745
|
|
|
160,945
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss/(gain) on foreign currency transactions, net
|
|
|
(382)
|
|
|
2,864
|
|
|
|
5,873
|
|
|
(5,668)
|
|
Loss on derivative instruments
|
|
|
(2,147)
|
|
|
2,140
|
|
|
|
(1,961)
|
|
|
3,302
|
|
Interest expense, net
|
|
|
984
|
|
|
1,020
|
|
|
|
3,767
|
|
|
3,883
|
|
Other expense/(income)
|
|
|
(529)
|
|
|
39
|
|
|
|
(257)
|
|
|
(101)
|
|
Income before taxes
|
|
|
47,473
|
|
|
18,970
|
|
|
|
178,323
|
|
|
159,529
|
|
Income tax provision
|
|
|
12,622
|
|
|
4,821
|
|
|
|
42,718
|
|
|
35,744
|
|
Net income
|
|
|
34,851
|
|
|
14,149
|
|
|
|
135,605
|
|
|
123,785
|
|
Less: Net income attributable to noncontrolling interests
|
|
|
115
|
|
|
391
|
|
|
|
1,773
|
|
|
1,992
|
|
Net income attributable to Sirona Dental Systems, Inc.
|
|
$
|
34,736
|
|
$
|
13,758
|
|
|
$
|
133,832
|
|
$
|
121,793
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per share (attributable to Sirona Dental Systems, Inc.
common shareholders):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Basic
|
|
$
|
0.63
|
|
$
|
0.25
|
|
|
$
|
2.41
|
|
$
|
2.19
|
|
- Diluted
|
|
$
|
0.62
|
|
$
|
0.24
|
|
|
$
|
2.36
|
|
$
|
2.13
|
|
Weighted average shares - basic
|
|
|
55,128,904
|
|
|
56,080,442
|
|
|
|
55,524,188
|
|
|
55,735,422
|
|
Weighted average shares - diluted
|
|
|
56,388,273
|
|
|
57,466,184
|
|
|
|
56,755,396
|
|
|
57,292,996
|
|
|
|
|
|
|
|
|
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
2012
|
|
|
September 30,
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
$'000s (except per share amounts)
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
151,088
|
|
$
|
345,859
|
|
Accounts receivable, net of allowance for doubtful accounts
|
|
|
|
|
|
|
|
of $1,408 and $1868, respectively
|
|
|
132,569
|
|
|
97,853
|
|
Inventories, net
|
|
|
81,007
|
|
|
93,028
|
|
Deferred tax assets
|
|
|
24,781
|
|
|
25,014
|
|
Prepaid expenses and other current assets
|
|
|
17,622
|
|
|
15,477
|
|
Income tax receivable
|
|
|
2,213
|
|
|
4,193
|
|
Total current assets
|
|
|
409,280
|
|
|
581,424
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net of accumulated depreciation
|
|
|
|
|
|
|
|
and amortization of $125,706 and $111,832, respectively
|
|
|
143,351
|
|
|
131,044
|
|
Goodwill
|
|
|
631,077
|
|
|
653,799
|
|
Investments
|
|
|
14
|
|
|
2,453
|
|
Restricted cash
|
|
|
-
|
|
|
655
|
|
Intangible assets, net of accumulated amortization of
|
|
|
|
|
|
|
|
$446,447 and $412,428, respectively
|
|
|
288,556
|
|
|
346,442
|
|
Other non-current assets
|
|
|
9,368
|
|
|
2,884
|
|
Deferred tax assets
|
|
|
12,888
|
|
|
7,427
|
|
Total assets
|
|
$
|
1,494,534
|
|
$
|
1,726,128
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
Trade accounts payable
|
|
$
|
51,961
|
|
$
|
48,697
|
|
Short-term debt and current portion of long-term debt
|
|
|
478
|
|
|
368,403
|
|
Income taxes payable
|
|
|
14,906
|
|
|
6,811
|
|
Deferred tax liabilities
|
|
|
817
|
|
|
1,108
|
|
Accrued liabilities and deferred income
|
|
|
118,075
|
|
|
110,207
|
|
Total current liabilities
|
|
|
186,237
|
|
|
535,226
|
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
75,000
|
|
|
-
|
|
Deferred tax liabilities
|
|
|
122,441
|
|
|
138,327
|
|
Other non-current liabilities
|
|
|
16,852
|
|
|
16,978
|
|
Pension related provisions
|
|
|
61,629
|
|
|
49,677
|
|
Deferred income
|
|
|
40,000
|
|
|
50,000
|
|
Total liabilities
|
|
|
502,159
|
|
|
790,208
|
|
|
|
|
|
|
|
|
|
Shareholders' equity
|
|
|
|
|
|
|
|
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none
issued and outstanding)
|
|
|
0
|
|
|
0
|
|
Common stock ($0.01 par value; 95,000,000 shares authorized;
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56,598,045 shares issued and 55,051,673 shares outstanding at
Sept. 30, 2012; 56,292,420 shares issued and 55,815,323
shares outstanding at Sept. 30, 2011
|
|
|
566
|
|
|
563
|
|
Additional paid-in capital
|
|
|
699,279
|
|
|
685,617
|
|
Treasury stock (at cost)
|
|
|
|
|
|
|
|
1,546,372 shares held at cost at Sept. 30, 2012; 477,097
shares held at cost at Sept. 30, 2011
|
|
|
(69,058)
|
|
|
(19,749)
|
|
Excess of purchase price over predecessor basis
|
|
|
(49,103)
|
|
|
(49,103)
|
|
Retained earnings
|
|
|
437,471
|
|
|
303,639
|
|
Accumulated other comprehensive income/(loss)
|
|
|
(29,797)
|
|
|
11,309
|
|
Total Sirona Dental Systems, Inc. shareholders' equity
|
|
|
989,358
|
|
|
932,276
|
|
Noncontrolling interests
|
|
|
3,017
|
|
|
3,644
|
|
|
|
|
|
|
|
|
|
Total shareholders' equity
|
|
|
992,375
|
|
|
935,920
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders' equity
|
|
$
|
1,494,534
|
|
$
|
1,726,128
|
|
|
|
|
|
|
|
|
|
|
|
SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended
September 30,
2012
|
|
|
|
Year ended
September 30,
2011
|
|
|
|
|
|
$'000s
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
$
|
135,605
|
|
|
$
|
123,785
|
|
Adjustments to reconcile net income to net
cash provided by operating activities
|
|
|
|
Depreciation and amortization
|
|
|
|
77,749
|
|
|
|
81,173
|
|
Compensation charge paid by shareholders
|
|
|
|
-
|
|
|
|
6,625
|
|
(Gain)/loss on disposal of property, plant and equipment
|
|
|
|
(91)
|
|
|
|
-
|
|
(Gain)/loss on derivative instruments
|
|
|
|
(1,961)
|
|
|
|
3,302
|
|
(Gain)/loss on foreign currency transactions
|
|
|
|
5,873
|
|
|
|
(5,668)
|
|
Deferred income taxes
|
|
|
|
(17,274)
|
|
|
|
(17,173)
|
|
Amortization of debt issuance cost
|
|
|
|
631
|
|
|
|
587
|
|
Share-based compensation expense
|
|
|
|
8,623
|
|
|
|
7,604
|
|
|
|
|
|
|
|
|
|
|
|
Changes in assets and liabilities
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
|
(38,301)
|
|
|
|
(14,202)
|
|
Inventories
|
|
|
|
8,824
|
|
|
|
(19,542)
|
|
Prepaid expenses and other current assets
|
|
|
|
(1,935)
|
|
|
|
8,861
|
|
Restricted cash
|
|
|
|
646
|
|
|
|
20
|
|
Other non-current assets
|
|
|
|
(290)
|
|
|
|
(453)
|
|
Trade accounts payable
|
|
|
|
4,600
|
|
|
|
6,191
|
|
Accrued interest on long-term debt
|
|
|
|
-
|
|
|
|
-
|
|
Accrued liabilities and deferred income
|
|
|
|
(6,674)
|
|
|
|
2,566
|
|
Other non-current liabilities
|
|
|
|
15,144
|
|
|
|
(2,997)
|
|
Income taxes receivable
|
|
|
|
1,954
|
|
|
|
(697)
|
|
Income taxes payable
|
|
|
|
8,246
|
|
|
|
(1,129)
|
|
Net cash provided by operating activities
|
|
|
$
|
201,369
|
|
|
$
|
178,853
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
|
Investment in property, plant and equipment
|
|
|
|
(47,131)
|
|
|
|
(56,958)
|
|
Proceeds from sale of property, plant and equipment
|
|
|
|
105
|
|
|
|
-
|
|
Prepayments for other assets
|
|
|
|
(4,612)
|
|
|
|
-
|
|
Purchase of intangible assets
|
|
|
|
(514)
|
|
|
|
(203)
|
|
Purchase of long-term investments
|
|
|
|
-
|
|
|
|
(145)
|
|
Acquisition of business, net of cash acquired
|
|
|
|
-
|
|
|
|
(20,836)
|
|
Sale of business, net of cash sold
|
|
|
|
-
|
|
|
|
-
|
|
Net cash used in investing activities
|
|
|
$
|
(52,152)
|
|
|
$
|
(78,142)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended
September 30,
2012
|
|
|
|
Year ended
September 30,
2011
|
|
|
|
|
|
$'000s
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
|
Repayments of short-term and long-term debt
|
|
|
$
|
(434,364)
|
|
|
$
|
-
|
|
Proceeds from borrowings
|
|
|
|
138,932
|
|
|
|
-
|
|
Purchase of treasury stock
|
|
|
|
(49,309)
|
|
|
|
(19,465)
|
|
Debt issuance cost
|
|
|
|
(2,765)
|
|
|
|
-
|
|
Purchase of shares from noncontrolling interest
|
|
|
|
-
|
|
|
|
-
|
|
Dividend distributions to noncontrolling interest
|
|
|
|
(1,689)
|
|
|
|
(487)
|
|
Common shares issued under share based
|
|
|
|
|
|
|
|
|
|
compensation plans
|
|
|
|
3,932
|
|
|
|
11,138
|
|
Tax effect of common shares exercised under share based
|
|
|
|
|
|
|
|
|
|
compensation plans
|
|
|
|
(181)
|
|
|
|
8,501
|
|
Net cash used in financing activities
|
|
|
$
|
(345,444)
|
|
|
$
|
(313)
|
|
|
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents
|
|
|
|
(196,227)
|
|
|
|
100,398
|
|
Effect of exchange rate change on cash and cash equivalents
|
|
|
|
1,456
|
|
|
|
(6,306)
|
|
Cash and cash equivalents at beginning of period
|
|
|
|
345,859
|
|
|
|
251,767
|
|
Cash and cash equivalents at end of period
|
|
|
$
|
151,088
|
|
|
$
|
345,859
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental information
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
|
$
|
2,966
|
|
|
$
|
3,380
|
|
Interest capitalized
|
|
|
|
237
|
|
|
|
450
|
|
Income taxes paid
|
|
|
|
44,795
|
|
|
|
46,923
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition of business
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
$
|
-
|
|
|
$
|
201
|
|
Non-current assets
|
|
|
|
-
|
|
|
|
47,255
|
|
Current liabilities
|
|
|
|
-
|
|
|
|
(269)
|
|
Non-current liabilities
|
|
|
|
-
|
|
|
|
(16,139)
|
|
|
|
|
|
-
|
|
|
|
31,048
|
|
Cash paid
|
|
|
|
-
|
|
|
|
(20,895)
|
|
Fair value of liabilities incurred
|
|
|
$
|
-
|
|
|
$
|
10,153
|
|
|
|
|
|
|
|
|
|
|
|
Sale of business, net of cash sold
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Non-current assets
|
|
|
|
-
|
|
|
|
-
|
|
Current liabilities
|
|
|
|
-
|
|
|
|
-
|
|
Non-current liabilities
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
$
|
-
|
|
|
$
|
-
|
Reconciliation of GAAP and Non-GAAP Information (unaudited)
HISTORICAL
Non-GAAP Adjusted Net Income Financial Measures (unaudited)
|
|
|
|
|
Three months ended September 30, 2012
|
|
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
|
Per Diluted Share
|
|
|
|
|
|
$'000s
|
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
|
|
|
|
|
$
|
34,736
|
|
$
|
0.62
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up
to fair values of intangible assets related to past business
combinations
|
|
|
$
|
11,419
|
|
$
|
3,092
|
|
$
|
8,327
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
|
(1,356)
|
|
|
(286)
|
|
|
(1,070)
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
|
(2,189)
|
|
|
(467)
|
|
|
(1,722)
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
|
|
|
$
|
40,271
|
|
$
|
0.71
|
|
Note: Effective tax rate of 26.6% for Q4 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, 2011
|
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
|
Per Diluted Share
|
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
shareholders
|
|
|
|
|
|
|
|
|
$
|
13,758
|
|
$
|
0.24
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash compensation charge paid by shareholders
|
|
|
|
6,625
|
|
$
|
-
|
|
$
|
6,625
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
|
$
|
13,531
|
|
$
|
2,716
|
|
$
|
10,815
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
|
4,216
|
|
|
925
|
|
|
3,291
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of short-term intra-group loans
|
|
|
|
5,664
|
|
|
1,241
|
|
|
4,423
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
|
|
|
$
|
38,912
|
|
$
|
0.68
|
|
Note: Effective tax rate of 18.8% for Q4 11, excluding the $6.6
million non-cash compensations expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full year ended September 30, 2012
|
|
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
|
Per Diluted Share
|
|
|
|
|
|
$'000s, except per share amount
|
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
shareholders
|
|
|
|
|
|
|
|
|
$
|
133,832
|
|
$
|
2.36
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
|
$
|
46,622
|
|
$
|
11,189
|
|
$
|
35,433
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
|
2,559
|
|
|
614
|
|
|
1,945
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of short-term intra-group loans
|
|
|
|
3,677
|
|
|
882
|
|
|
2,795
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
|
|
|
$
|
174,005
|
|
$
|
3.07
|
|
Note: Effective tax rate of 24% for FY 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Full year ended September 30, 2011
|
|
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
|
Per Diluted Share
|
|
|
|
|
|
$'000s, except per share amount
|
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
shareholders
|
|
|
|
|
|
|
|
|
$
|
121,793
|
|
$
|
2.13
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash compensation charge paid by shareholders
|
|
|
|
6,625
|
|
$
|
-
|
|
$
|
6,625
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
|
$
|
53,562
|
|
$
|
11,523
|
|
$
|
42,039
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
|
499
|
|
|
107
|
|
|
392
|
|
|
|
|
Unrealized, non-cash loss/(gain) on revaluation of the carrying
value of short-term intra-group loans
|
|
|
|
1,045
|
|
|
225
|
|
|
820
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
|
|
|
$
|
171,669
|
|
$
|
3.00
|
|
Note: Effective tax rate of 21.5% for the full year FY11, excluding
the $6.6 million non-cash compensations expense
|
|
|
|
|
|
|
Non-GAAP Adjusted Operating Income (unaudited)
|
|
|
|
|
Three months ended September 30,
|
|
|
|
|
Full year ended September 30,
|
|
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
2012
|
|
|
2011
|
|
|
|
|
$ millions
|
|
|
|
$ millions
|
|
GAAP operating income
|
|
$
|
45,399
|
|
$
|
25,033
|
|
|
|
$
|
185,745
|
|
$
|
160,945
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense
|
|
|
11,743
|
|
|
13,874
|
|
|
|
|
47,949
|
|
|
54,941
|
|
Non-cash compensation charge paid by shareholders
|
|
|
|
|
|
6,625
|
|
|
|
|
|
|
|
6,625
|
|
Non-GAAP adjusted operating income
|
|
$
|
57,142
|
|
$
|
45,532
|
|
|
|
$
|
233,694
|
|
$
|
222,511
|
FORWARD-LOOKING
Non-GAAP Adjusted EPS Guidance (unaudited)
|
|
|
Low End of Guidance
|
|
|
|
|
|
|
Pre Tax
|
|
Tax Impact
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
|
|
|
$ millions, except per share amount
|
|
|
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
|
|
$
|
160
|
|
$
|
2.83
|
|
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
38
|
|
$
|
9
|
|
$
|
29
|
|
|
|
|
|
|
(Gain)/Loss Foreign Currency Transactions, net**
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
|
|
|
|
(Gain)/Loss on derivative instruments, net**
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
$
|
189
|
|
$
|
3.33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
High End of Guidance
|
|
|
|
|
|
|
Pre Tax
|
|
Tax Impact
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
|
|
|
$ millions, except per share amount
|
|
|
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
shareholders
|
|
|
|
|
|
$
|
166
|
|
$
|
2.93
|
|
|
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
|
38
|
|
$
|
9
|
|
$
|
29
|
|
|
|
|
|
|
(Gain)/Loss Foreign Currency Transactions, net**
|
|
$
|
-
|
|
|
-
|
|
$
|
-
|
|
|
|
|
|
|
(Gain)/Loss on derivative instruments, net**
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
|
|
$
|
195
|
|
$
|
3.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
**We are unable to provide estimates for these items because we are
unable to predict the 2013 and long-term impact of foreign exchange
due to unpredictability of future changes in foreign exchange rates.
|
To supplement our consolidated financial statements, we use
the following non-GAAP financial measures: (i) non-GAAP adjusted net
income, and non-GAAP adjusted earnings per diluted share, which exclude,
as applicable, amortization and depreciation expense resulting from the
step-up to fair values of intangible and tangible assets related to past
business combinations, unrealized, non-cash loss/(gain) on revaluation
of the carrying value of the $-denominated exclusivity fee, unrealized,
non-cash loss/(gain) on revaluation of the carrying value of short-term
intra-group loans and any related tax effects; and (ii) non-GAAP
adjusted operating income, which excludes amortization.
Commencing with fiscal 2013 guidance, and to supplement our business
outlook, we use the following non-GAAP financial measures: non-GAAP
adjusted net income, and non-GAAP adjusted earnings per diluted share,
which exclude, as applicable, amortization and depreciation expense
resulting from the step-up to fair values of intangible and tangible
assets related to past business combinations, gain/loss on foreign
currency transactions, gain/loss on derivative instruments and any
related tax effects. Also set forth above under the heading
“FORWARD-LOOKING” are reconciliations of forward-looking non-GAAP
financial measures to the most directly comparable GAAP financial
measures.
Management recognizes that the use of these non-GAAP measures has
limitations, including the fact that they might not be comparable with
similar non-GAAP measures used by other companies and that management
must exercise judgment in determining which types of charges and other
items should be excluded from its non-GAAP financial measures. Management
currently compensates for these limitations by providing full disclosure
of each non-GAAP financial measure and a reconciliation to the most
directly comparable GAAP measure. The presentation of this financial
information is not intended to be considered in isolation or as a
substitute for, or superior to, the financial information prepared and
presented in accordance with GAAP.
We use these non-GAAP financial measures for financial and
operational decision making and as a means to evaluate period-to-period
comparisons. Our management believes that these non-GAAP financial
measures provide meaningful supplemental information regarding our "core
operating performance". Management believes that "core operating
performance" represents Sirona’s operating performance in the ordinary,
ongoing and customary course of its operations. Accordingly, management
excludes from "core operating performance" the impact of
acquisition-related intangible depreciation and amortization in order to
compare our underlying financial performance to prior periods, certain
charges related to currency revaluation of assets and liabilities that
do not reflect our period-to-period core operating performance, and to
the extent relevant in a particular period, any other cash or non-cash
items that management does not view as indicative of its on-going
operating performance. We believe that both management and
investors benefit from referring to these non-GAAP financial measures in
assessing our performance and when planning, forecasting and analyzing
future periods. These non-GAAP financial measures also facilitate
management's internal evaluation of period-to-period comparisons. We
believe these non-GAAP financial measures are useful to investors both
because (1) they allow for greater transparency with respect to key
metrics used by management in its financial and operational decision
making and (2) they are provided to and used by our institutional
investors and the analyst community to facilitate comparisons with prior
and subsequent reporting periods.
Constant Currency: We have included certain revenue information in
this press release on a constant currency basis. This information is a
non-GAAP financial measure. We additionally present revenue on a
constant currency basis because we believe it facilitates a comparison
of our operating results from period to period without regard to changes
resulting solely from fluctuations in currency rates.
Sirona calculates constant currency revenue growth by comparing
current period revenues to prior period revenues with both periods
converted at the U.S. Dollar/Euro average foreign exchange rate for each
month of the current period. The average exchange rate for the three
months ended September 30, 2012, was $1.25141. The average exchange rate
for the fiscal year ended September 30, 2012, was $1.29922 and varied
from $1.23114 to $1.37045. For the three months and full year ended
September 30, 2011, an average exchange rate converting Euro denominated
revenues into U.S. Dollars of $1.41653 and $1.39570, respectively, was
applied.
Our forecasted 2013 constant currency net revenue guidance excludes
the impact of foreign exchange. We are unable to reconcile our projected
2013 constant currency net revenue growth to our full-year projected
2013 net revenue growth because we are unable to predict the 2013 and
long-term impact of foreign exchange due to the unpredictability of
future changes in foreign exchange rates. Therefore, we are unable to
provide a reconciliation of these measures.
The following is a reconciliation of (i) the historical non-GAAP
adjusted earnings per diluted share reporting to (ii) non-GAAP adjusted
earnings per diluted share calculated on the same basis as the new
metric we announced today for fiscal 2013 guidance.
|
|
|
GAAP Reconciliation to Old Non-GAAP Three
months ended September 30, 2012
|
|
GAAP Reconciliation to New Non-GAAP Three
months ended September 30, 2012
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
$
|
34,736
|
|
$
|
0.62
|
|
|
|
|
|
$
|
34,736
|
|
$
|
0.62
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
11,419
|
|
|
3,092
|
|
|
|
8,327
|
|
|
|
$
|
11,419
|
|
|
3,092
|
|
|
|
8,327
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
(1,356
|
)
|
|
(286
|
)
|
|
|
(1,070)
|
|
|
|
|
(1,356
|
)
|
|
(286
|
)
|
|
|
(1,070)
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
(2,189
|
)
|
|
(467
|
)
|
|
|
(1,722)
|
|
|
|
|
(2,189
|
)
|
|
(467
|
)
|
|
|
(1,722)
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
3,163
|
|
|
841
|
|
|
|
2,322
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(2,147
|
)
|
|
(571
|
)
|
|
|
(1,576)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
40,271
|
|
$
|
0.71
|
|
|
|
|
|
$
|
41,017
|
|
$
|
0.73
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an effective tax rate of 26.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Reconciliation to Old Non-GAAP Three
months ended June 30, 2012
|
|
GAAP Reconciliation to New Non-GAAP Three
months ended June 30, 2012
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
$
|
30,298
|
|
$
|
0.53
|
|
|
|
|
|
$
|
30,298
|
|
$
|
0.53
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
11,537
|
|
|
2,654
|
|
|
|
8,883
|
|
|
|
$
|
11,537
|
|
|
2,654
|
|
|
|
8,883
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
3,153
|
|
|
725
|
|
|
|
2,428
|
|
|
|
|
3,153
|
|
|
725
|
|
|
|
2,428
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
4,822
|
|
|
1,109
|
|
|
|
3,713
|
|
|
|
|
4,822
|
|
|
1,109
|
|
|
|
3,713
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(5,300
|
)
|
|
(1,219
|
)
|
|
|
(4,081)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
2,686
|
|
|
618
|
|
|
|
2,068
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
45,322
|
|
$
|
0.80
|
|
|
|
|
|
$
|
43,309
|
|
$
|
0.76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 23%
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended March 31, 2012
|
|
Three months ended March 31, 2012
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
30,521
|
|
$
|
0.54
|
|
|
|
|
|
$
|
30,521
|
|
$
|
0.54
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
11,707
|
|
|
2,693
|
|
|
|
9,014
|
|
|
|
$
|
11,707
|
|
|
2,693
|
|
|
|
9,014
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
(1,742
|
)
|
|
(401
|
)
|
|
|
(1,341)
|
|
|
|
|
(1,742
|
)
|
|
(401
|
)
|
|
|
(1,341)
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
(2,303
|
)
|
|
(530
|
)
|
|
|
(1,773)
|
|
|
|
|
(2,303
|
)
|
|
(530
|
)
|
|
|
(1,773)
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
5,395
|
|
|
1,241
|
|
|
|
4,154
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(2,936
|
)
|
|
(675
|
)
|
|
|
(2,261)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
36,421
|
|
$
|
0.64
|
|
|
|
|
|
$
|
38,314
|
|
$
|
0.67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 23%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended December 31, 2011
|
|
Three months ended December 31, 2011
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
$
|
38,277
|
|
$
|
0.67
|
|
|
|
|
|
$
|
38,277
|
|
$
|
0.67
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
11,959
|
|
|
2,751
|
|
|
|
9,208
|
|
|
|
$
|
11,959
|
|
|
2,751
|
|
|
|
9,208
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
2,503
|
|
|
576
|
|
|
|
1,927
|
|
|
|
|
2,503
|
|
|
576
|
|
|
|
1,927
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
3,347
|
|
|
770
|
|
|
|
2,577
|
|
|
|
|
3,347
|
|
|
770
|
|
|
|
2,577
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(3,620
|
)
|
|
(833
|
)
|
|
|
(2,787)
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
436
|
|
|
100
|
|
|
|
336
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
51,990
|
|
$
|
0.91
|
|
|
|
|
|
$
|
49,538
|
|
$
|
0.87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 23%
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended September 30, 2011
|
|
Three months ended September 30, 2011
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
13,758
|
|
|
0.24
|
|
|
|
|
|
$
|
13,758
|
|
$
|
0.24
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
13,531
|
|
|
2,716
|
|
|
|
10,815
|
|
|
|
$
|
13,531
|
|
|
2,716
|
|
|
|
10,815
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
4,216
|
|
|
925
|
|
|
|
3,291
|
|
|
|
|
4,216
|
|
|
925
|
|
|
|
3,291
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
5,664
|
|
|
1,241
|
|
|
|
4,423
|
|
|
|
|
5,664
|
|
|
1,241
|
|
|
|
4,423
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(7,016
|
)
|
|
(1,319
|
)
|
|
|
(5,697)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
2,140
|
|
|
402
|
|
|
|
1,738
|
|
|
|
Non-cash compensation charge paid by shareholders
|
|
|
6,625
|
|
|
-
|
|
|
|
6,625
|
|
|
|
|
6,625
|
|
|
-
|
|
|
|
6,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
38,912
|
|
$
|
0.68
|
|
|
|
|
|
$
|
34,953
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an effective tax rate of 18.8%,
excluding the $6.6 million non-cash compensation expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended June 30, 2011
|
|
Three months ended June 30, 2011
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
36,331
|
|
$
|
0.63
|
|
|
|
|
|
$
|
36,331
|
|
$
|
0.63
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
13,693
|
|
|
3,012
|
|
|
|
10,681
|
|
|
|
$
|
13,693
|
|
|
3,012
|
|
|
|
10,681
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
(1,248
|
)
|
|
(275
|
)
|
|
|
(973)
|
|
|
|
|
(1,248
|
)
|
|
(275
|
)
|
|
|
(973)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
(1,618
|
)
|
|
(356
|
)
|
|
|
(1,262)
|
|
|
|
|
(1,618
|
)
|
|
(356
|
)
|
|
|
(1,262)
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
(569
|
)
|
|
(131
|
)
|
|
|
(438)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
|
1,081
|
|
|
249
|
|
|
|
832
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
44,776
|
|
$
|
0.78
|
|
|
|
|
|
$
|
45,170
|
|
$
|
0.78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 21.5%
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended March 31, 2011
|
|
Three months ended March 31, 2011
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
29,312
|
|
$
|
0.51
|
|
|
|
|
|
$
|
29,312
|
|
$
|
0.51
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
13,192
|
|
2,902
|
|
|
10,290
|
|
|
|
$
|
13,192
|
|
2,902
|
|
|
10,290
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
(3,878)
|
|
(853)
|
|
|
(3,025)
|
|
|
|
|
(3,878)
|
|
(853)
|
|
|
(3,025)
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
(4,347)
|
|
(956)
|
|
|
(3,391)
|
|
|
|
|
(4,347)
|
|
(956)
|
|
|
(3,391)
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
3,889
|
|
856
|
|
|
3,033
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
(1,554)
|
|
(342)
|
|
|
(1,212)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
33,186
|
|
$
|
0.58
|
|
|
|
|
|
$
|
35,008
|
|
$
|
0.61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 21.5%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Three months ended December 31, 2010
|
|
Three months ended December 31, 2010
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
42,392
|
|
$
|
0.75
|
|
|
|
|
|
$
|
42,392
|
|
$
|
0.75
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
13,146
|
|
2,892
|
|
|
10,254
|
|
|
|
$
|
13,146
|
|
2,892
|
|
|
10,254
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
1,408
|
|
310
|
|
|
1,098
|
|
|
|
|
1,408
|
|
310
|
|
|
1,098
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
1,346
|
|
296
|
|
|
1,050
|
|
|
|
|
1,346
|
|
296
|
|
|
1,050
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
(3,515)
|
|
(773)
|
|
|
(2,742)
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
1,635
|
|
360
|
|
|
1,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
54,794
|
|
$
|
0.96
|
|
|
|
|
|
$
|
53,328
|
|
$
|
0.94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an estimated effective tax rate
of 21.5%
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Year ended September 30, 2012
|
|
Year ended September 30, 2012
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable
|
|
|
|
$
|
133,832
|
|
$
|
2.36
|
|
|
|
|
|
$
|
133,832
|
|
$
|
2.36
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
46,622
|
|
11,189
|
|
|
35,433
|
|
|
|
$
|
46,622
|
|
11,189
|
|
|
35,433
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
2,559
|
|
614
|
|
|
1,945
|
|
|
|
|
2,559
|
|
614
|
|
|
1,945
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
3,677
|
|
882
|
|
|
2,795
|
|
|
|
|
3,677
|
|
882
|
|
|
2,795
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
(363)
|
|
30
|
|
|
(392)
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
-
|
|
-
|
|
|
-
|
|
|
|
|
(1,961)
|
|
(528)
|
|
|
(1,433)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
174,005
|
|
$
|
3.07
|
|
|
|
|
|
$
|
172,178
|
|
$
|
3.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an effective tax rate of 24%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Reconciliation to Old Non-GAAP
|
|
GAAP Reconciliation to New Non-GAAP
|
|
|
|
Year ended September 30, 2011
|
|
Year ended September 30, 2011
|
|
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
Pre Tax
|
|
Tax Impact*
|
|
After Tax
|
|
Per Diluted Share
|
|
|
|
$'000s, except per share amount
|
|
|
|
$'000s, except per share amount
|
|
|
|
GAAP net income attributable to Sirona Dental Systems, Inc.
Shareholders
|
|
|
|
$
|
121,793
|
|
$
|
2.13
|
|
|
|
|
|
$
|
121,793
|
|
$
|
2.13
|
|
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation expense resulting from the step-up to
fair values of intangible assets related to past business
combinations
|
|
$
|
53,562
|
|
11,523
|
|
|
42,039
|
|
|
|
$
|
53,562
|
|
11,523
|
|
|
42,039
|
|
|
|
(Gain)/loss on foreign currency transactions, net
|
|
|
|
|
|
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of the $-denominated exclusivity fee
|
|
|
499
|
|
107
|
|
|
392
|
|
|
|
|
499
|
|
107
|
|
|
392
|
|
|
|
Unrealized, non-cash (gain)/loss on revaluation of the carrying
value of short-term intra-group loans
|
|
|
1,046
|
|
225
|
|
|
821
|
|
|
|
|
1,046
|
|
225
|
|
|
821
|
|
|
|
(Gain)/loss on other foreign currency transactions
|
|
(7,211)
|
|
|
|
(1,368)
|
|
|
(5,843)
|
|
|
|
(Gain)/loss on derivative instruments
|
|
|
|
|
|
|
3,302
|
|
669
|
|
|
2,633
|
|
|
|
Non-cash compensation charge paid by shareholders
|
|
|
6,625
|
|
-
|
|
|
6,625
|
|
|
|
|
6,625
|
|
-
|
|
|
6,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjusted net income attributable to Sirona Dental
Systems, Inc. shareholders
|
|
|
|
$
|
171,670
|
|
$
|
3.00
|
|
|
|
|
|
$
|
168,460
|
|
$
|
2.94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* tax impact calculated using an effective tax rate of 21.5%,
excluding the $6.6 million non-cash compensation expense
|
